Want to join the conversation?
$AMGN Amgen today announced submission of NDA with United States Food& Drug Administration for etelcalcetide (formerly AMG 416) for treatment of secondary hyperparathyroidism in patients with chronic kidney disease on hemodialysis. If approved, etelcalcetide will be the first calcimimetic agent that can be administered IV at end of dialysis session
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.